<DOC>
	<DOCNO>NCT00741468</DOCNO>
	<brief_summary>This study ass possible drug-drug interaction specific isoenzymes total study duration 6-8 week . Blood sample collect pre post-dose , urine sample collect post dose analyze .</brief_summary>
	<brief_title>Open-Label , Multiple-Dose , Non-Randomized Study Assess Drug-Drug Interactions Proellex® Female Subjects</brief_title>
	<detailed_description>This open-label , multiple-dose , non-randomized study ass drug-drug interaction Proellex® cytochrome P450 isoenzymes healthy female subject . On Day 1 , follow overnight fast morning void bladder , subject administer CYP probe drug orally . Serial blood sample collect pre-dose post-dose . Subjects administer two Proellex® 25 mg capsule ( 50 mg total dose ) approximately 0800 hour Day 2 0700 hour Days 3 8 . One hour administration Proellex® Day 8 , five CYP probe drug administer blood urine sample collect Day 1 . Blood sample determination plasma concentration CDB-4124 metabolite CDB-4453 collect pre-dose ( trough ) Days 6 , 7 , 8 determine steady-state condition achieve . Samples also collect Day 8 1 , 2 , 8 24 hour administration Proellex® determine plasma concentration CDB-4124 CDB-4453 .</detailed_description>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Tolbutamide</mesh_term>
	<criteria>Healthy adult females A body mass index 18 30 kg/m2 , inclusive Negative urine drug alcohol screen . Significant medical condition , Significant physical examination find Clinical laboratory ECG abnormality CYP2D6 `` poor metabolizer ''</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Drug-drug interaction</keyword>
	<keyword>DDI</keyword>
</DOC>